OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma

January 12th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Dr. Albala on the Benefits of Robotic Surgery in Prostate Cancer

January 12th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses the benefits associated with robotic surgery in the treatment of patients with prostate cancer.

Dr. Goy on Combination Therapies in Mantle Cell Lymphoma

January 12th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Dr. Rolfo on Precision Medicine in Lung Cancer

January 12th 2017

Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

Dr. Mamounas on Extended Letrozole Therapy for Breast Cancer

January 11th 2017

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the phase III trial for extended letrozole (Femara) therapy for patients with breast cancer.

Dr. Chaudhary on History of CAR T-Cell Therapy

January 11th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the history of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

January 11th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses novel agents or clinical trials in development designed to help guide treatment decisions for patients with prostate cancer.

Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer

January 11th 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Samuel Smith on Adherence in Menopausal Women at Risk for Breast Cancer

January 11th 2017

Samuel Smith, PhD, university academic fellow at the University of Leeds, discusses a breast cancer prevention trial that measured adherence to preventative medication in women experiencing menopausal symptoms.

Dr. Soliman on Impact of MammaPrint in Patients With Early-Stage Breast Cancer

January 11th 2017

Hatem Soliman, MD, associate member of The Center for Women’s Oncology at the Moffitt Cancer Center discusses the prospective registry IMPACt study, which measured the impact of the MammaPrint 70-gene Breast Cancer Recurrence Assay in the routine management of women with early-stage breast cancer.

Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

January 10th 2017

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Dr. Sklar on the Role of Nivolumab in Bladder Cancer

January 10th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.

Dr. Swanson on Surgical Choices for Multifocal Lung Cancer

January 10th 2017

Scott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.

Dr. Bueno on Gene Expression Signatures for Squamous Cell Lung Carcinoma

January 10th 2017

Raphael Bueno, MD, chief, Division of Thoracic Surgery co-director, Brigham and Women’s Lung Center, vice chairman of Surgery for Cancer and Translational Research, professor at Harvard Medical School, discusses gene expression signatures for squamous cell lung carcinoma.

Nab-Paclitaxel as Neoadjuvant Therapy for Breast Cancer

January 10th 2017

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

Dr. Kosari on Antitumor Immunity in Small Cell Lung Cancer

January 10th 2017

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Dr. Kristeleit on the Efficacy of Rucaparib in Ovarian Cancer

January 10th 2017

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.

Dr. Stein on Trials Investigating Biomarkers in Prostate Cancer

January 9th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.

Dr. Hassan on Immunotherapy in Malignant Pleural Mesothelioma

January 9th 2017

Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

Dr. Birrer on Prevalence of Cervical Cancer in the United States

January 9th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.